Merck is attracting bullish attention due to its low valuation and strong dividend, but dark clouds hover over its future.

Dr. Reddy’s Laboratories has partnered with global biotech firm Alvotech to co-develop and commercialize a biosimilar of ...

Alvotech and Dr. Reddy's will co-develop a biosimilar to Keytruda, aiming to expand global access to cancer treatment alternatives.

LIC’s shareholding in Dr. Reddy’s Laboratories rose from 5.6% at the end of September 2024 to 6.5% by December 2024, and ...

Alvotech , a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Hyderabad-based Dr. Reddy’s Laboratories Ltd, on Thursday ...

Dr. Reddy's Laboratories and Alvotech are collaborating to develop, manufacture, and commercialize a biosimilar version of ...

Dr. Reddy teams up with Alvotech to co-develop and commercialize a biosimilar of MRK's Keytruda, aiming to expand its biosimilars footprint.

Dr. Reddy's Laboratories and Alvotech have partnered to co-develop, manufacture, and commercialize a biosimilar of Keytruda ...

Alvotech (ALVO) and Dr. Reddy’s Laboratories (RDY) have entered into a collaboration and license agreement to co-develop, ...

The former workers cited various reasons why they think Novo was cautious: its conservative culture and history of investing ...

Shares of Dr. Reddy’s Laboratories Ltd ADR (NYSE:RDY) climbed 3.1% in premarket trading today following the announcement of a collaboration and license agreement with Alvotech to co-develop, ...

Alvotech and Dr. Reddy's collaborate to develop biosimilar Keytruda, expanding global access to cancer treatment options.